{"protocolSection": {"identificationModule": {"nctId": "NCT00783198", "orgStudyIdInfo": {"id": "P05233"}, "secondaryIdInfos": [{"id": "2008-003863-38", "type": "EUDRACT_NUMBER"}, {"id": "MK-3641-002", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "ALK-Abell\u00f3 A/S", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)", "officialTitle": "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-30", "studyFirstSubmitQcDate": "2008-10-30", "studyFirstPostDateStruct": {"date": "2008-10-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-04-25", "resultsFirstSubmitQcDate": "2014-06-09", "resultsFirstPostDateStruct": {"date": "2014-07-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-18", "lastUpdatePostDateStruct": {"date": "2017-03-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "ALK-Abell\u00f3 A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season."}, "conditionsModule": {"conditions": ["Rhinitis; Allergic, With Asthma", "Conjunctivitis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 565, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SCH 39641 6 Amb a 1-U", "type": "EXPERIMENTAL", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks", "interventionNames": ["Biological: SCH 39641 6 Amb a 1-U"]}, {"label": "SCH 39641 12 Amb a 1-U", "type": "EXPERIMENTAL", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks", "interventionNames": ["Biological: SCH 39641 12 Amb a 1-U"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "SCH 39641 6 Amb a 1-U", "description": "SCH 39641 6 Amb a 1-U sublingual tablets administered once daily", "armGroupLabels": ["SCH 39641 6 Amb a 1-U"], "otherNames": ["MK-3641"]}, {"type": "BIOLOGICAL", "name": "SCH 39641 12 Amb a 1-U", "description": "SCH 39641 12 Amb a 1-U sublingual tablets administered once daily", "armGroupLabels": ["SCH 39641 12 Amb a 1-U"], "otherNames": ["MK-3641"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "matching placebo sublingual tablets administered once daily", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)", "description": "The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18). Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36. The sum of the rhinoconjunctivitis DSS and DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means for DSS+DMS were converted to adjusted means based on an analysis of variance (ANOVA) model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "timeFrame": "The 15-day period during the ragweed season with the highest moving pollen average"}], "secondaryOutcomes": [{"measure": "Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS", "description": "The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18). Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36. The sum of the rhinoconjunctivitis DSS and DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means for DSS+DMS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "timeFrame": "Approximately 5 weeks"}, {"measure": "Average Rhinoconjunctivitis DSS for the Peak RS", "description": "The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjuntivitis symptoms. Raw means for DSS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "timeFrame": "The 15-day period during the ragweed season with the highest moving pollen average"}, {"measure": "Average Rhinoconjunctivitis DSS for the Entire RS", "description": "The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjuntivitis symptoms. Raw means for DSS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "timeFrame": "Approximately 5 weeks"}, {"measure": "Average Rhinoconjunctivitis DMS for the Peak RS", "description": "Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36, with a lower score indicating less rhinoconjuntivitis medication use. Raw means for DMS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "timeFrame": "The 15-day period during the ragweed season with the highest moving pollen average"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Must have a clinical history of significant ragweed-induced allergic rhinoconjunctivitis of at least 2 years duration, with or without asthma and have received treatment during the previous RS.\n* Must have a positive skin prick test response to Ambrosia artemisiifolia at Screening Visit.\n* Must be positive for specific immunoglobulin E (IgE) against Ambrosia artemisiifolia at Screening Visit.\n* Must have an forced expiratory volume in 1 second (FEV1) of at least 70% of predicted at Screening Visit.\n* Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor\n\nExclusion Criteria:\n\n* Clinical history of symptomatic seasonal allergic rhinitis and/or asthma having received regular medication, due to another allergen during or potentially overlapping the RS.\n* Clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed.\n* Receipt of an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).\n* Clinical history of severe asthma.\n* Asthma requiring medium or high dose inhaled corticosteroids.\n* History of anaphylaxis with cardiorespiratory symptoms.\n* History of chronic urticaria and angioedema.\n* Clinical history of chronic sinusitis 2 years prior to the Screening Visit.\n* Current severe atopic dermatitis.\n* Breast-feeding, pregnant, or intending to become pregnant.\n* Had previous treatment by immunotherapy with ragweed allergen or any other allergen 5 years prior to Screening Visit.\n* History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (except for Ambrosia artemisiifolia), rescue medications, or self-injectable epinephrine.\n* History of self-injectable epinephrine use.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "referencesModule": {"references": [{"pmid": "26507708", "type": "DERIVED", "citation": "Christensen LH, Ipsen H, Nolte H, Maloney J, Nelson HS, Weber R, Lund K. Short ragweeds is highly cross-reactive with other ragweeds. Ann Allergy Asthma Immunol. 2015 Dec;115(6):490-495.e1. doi: 10.1016/j.anai.2015.09.016. Epub 2015 Oct 21."}, {"pmid": "24836393", "type": "DERIVED", "citation": "Nolte H, Amar N, Bernstein DI, Lanier BQ, Creticos P, Berman G, Kaur A, Hebert J, Maloney J. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol. 2014 Jul;113(1):93-100.e3. doi: 10.1016/j.anai.2014.04.018. Epub 2014 May 14."}, {"pmid": "25788949", "type": "DERIVED", "citation": "Kim H, Waserman S, Hebert J, Blaiss M, Nelson H, Creticos P, Kaur A, Maloney J, Li Z, Nolte H. Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis. Allergy Asthma Clin Immunol. 2014 Nov 10;10(1):55. doi: 10.1186/1710-1492-10-55. eCollection 2014."}, {"pmid": "23706715", "type": "DERIVED", "citation": "Nolte H, Hebert J, Berman G, Gawchik S, White M, Kaur A, Liu N, Lumry W, Maloney J. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013 Jun;110(6):450-456.e4. doi: 10.1016/j.anai.2013.03.013. Epub 2013 May 2."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "FG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "FG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "190"}, {"groupId": "FG001", "numSubjects": "187"}, {"groupId": "FG002", "numSubjects": "188"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "133"}, {"groupId": "FG001", "numSubjects": "144"}, {"groupId": "FG002", "numSubjects": "146"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "43"}, {"groupId": "FG002", "numSubjects": "42"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "20"}]}, {"type": "Noncompliance with protocol", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "10"}]}, {"type": "Did not meet protocol eligibility", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Administrative", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "BG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "BG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "190"}, {"groupId": "BG001", "value": "187"}, {"groupId": "BG002", "value": "188"}, {"groupId": "BG003", "value": "565"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.3", "spread": "9.00"}, {"groupId": "BG001", "value": "34.9", "spread": "9.41"}, {"groupId": "BG002", "value": "35.9", "spread": "9.13"}, {"groupId": "BG003", "value": "35.4", "spread": "9.17"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "93"}, {"groupId": "BG003", "value": "286"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "95"}, {"groupId": "BG003", "value": "279"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)", "description": "The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18). Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36. The sum of the rhinoconjunctivitis DSS and DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means for DSS+DMS were converted to adjusted means based on an analysis of variance (ANOVA) model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "populationDescription": "The Full Analysis Set (FAS) population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement. A total of 5 participants at one site were excluded from all efficacy analyses due to Good Clinical Practice (GCP) issues.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "The 15-day period during the ragweed season with the highest moving pollen average", "groups": [{"id": "OG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "159"}, {"groupId": "OG002", "value": "164"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.70", "spread": "0.563", "lowerLimit": "-2.95", "upperLimit": "-0.57"}, {"groupId": "OG001", "value": "6.22", "spread": "0.543", "lowerLimit": "-3.41", "upperLimit": "-1.07"}, {"groupId": "OG002", "value": "8.46", "spread": "0.521", "lowerLimit": "NA", "upperLimit": "NA"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0039", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.95", "ciUpperLimit": "-0.57", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.41", "ciUpperLimit": "-1.07", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}]}, {"type": "SECONDARY", "title": "Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS", "description": "The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18). Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36. The sum of the rhinoconjunctivitis DSS and DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means for DSS+DMS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "populationDescription": "The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement. A total of 5 participants at one site were excluded from all efficacy analyses due to GCP issues.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Approximately 5 weeks", "groups": [{"id": "OG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "166"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.92", "spread": "0.467", "lowerLimit": "-2.08", "upperLimit": "-0.09"}, {"groupId": "OG001", "value": "5.21", "spread": "0.450", "lowerLimit": "-2.78", "upperLimit": "-0.82"}, {"groupId": "OG002", "value": "7.01", "spread": "0.434", "lowerLimit": "NA", "upperLimit": "NA"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0320", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.08", "ciUpperLimit": "-0.09", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.78", "ciUpperLimit": "-0.82", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}]}, {"type": "SECONDARY", "title": "Average Rhinoconjunctivitis DSS for the Peak RS", "description": "The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjuntivitis symptoms. Raw means for DSS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "populationDescription": "The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement. A total of 5 participants at one site were excluded from all efficacy analyses due to GCP issues.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "The 15-day period during the ragweed season with the highest moving pollen average", "groups": [{"id": "OG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "159"}, {"groupId": "OG002", "value": "164"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.81", "spread": "0.362", "lowerLimit": "-1.54", "upperLimit": "-0.01"}, {"groupId": "OG001", "value": "4.65", "spread": "0.349", "lowerLimit": "-1.70", "upperLimit": "-0.19"}, {"groupId": "OG002", "value": "5.59", "spread": "0.335", "lowerLimit": "NA", "upperLimit": "NA"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0472", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.54", "ciUpperLimit": "-0.01", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0144", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.70", "ciUpperLimit": "-0.19", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}]}, {"type": "SECONDARY", "title": "Average Rhinoconjunctivitis DSS for the Entire RS", "description": "The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjuntivitis symptoms. Raw means for DSS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "populationDescription": "The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement. A total of 5 participants at one site were excluded from all efficacy analyses due to GCP issues.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Approximately 5 weeks", "groups": [{"id": "OG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "166"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.41", "spread": "0.306", "lowerLimit": "-1.11", "upperLimit": "0.19"}, {"groupId": "OG001", "value": "4.05", "spread": "0.295", "lowerLimit": "-1.46", "upperLimit": "-0.18"}, {"groupId": "OG002", "value": "4.87", "spread": "0.285", "lowerLimit": "NA", "upperLimit": "NA"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1686", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.11", "ciUpperLimit": "0.19", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0125", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.46", "ciUpperLimit": "-0.18", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}]}, {"type": "SECONDARY", "title": "Average Rhinoconjunctivitis DMS for the Peak RS", "description": "Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36, with a lower score indicating less rhinoconjuntivitis medication use. Raw means for DMS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.", "populationDescription": "The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement. A total of 5 participants at one site were excluded from all efficacy analyses due to GCP issues.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "The 15-day period during the ragweed season with the highest moving pollen average", "groups": [{"id": "OG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "159"}, {"groupId": "OG002", "value": "164"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.89", "spread": "0.314", "lowerLimit": "-1.65", "upperLimit": "-0.32"}, {"groupId": "OG001", "value": "1.57", "spread": "0.303", "lowerLimit": "-1.95", "upperLimit": "-0.64"}, {"groupId": "OG002", "value": "2.87", "spread": "0.291", "lowerLimit": "NA", "upperLimit": "NA"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0039", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.65", "ciUpperLimit": "-0.32", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.95", "ciUpperLimit": "-0.64", "estimateComment": "ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 53 weeks", "description": "A total of 5 participants (2 in the SCH 39641 6 Amb a 1-U group, 1 in the SCH 39641 12 Amb a 1-U group and 2 in the Placebo group) at one site were excluded from all safety analyses due to GCP issues. Adverse events are reported for the remaining participants.", "eventGroups": [{"id": "EG000", "title": "SCH 39641 6 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 188, "otherNumAffected": 124, "otherNumAtRisk": 188}, {"id": "EG001", "title": "SCH 39641 12 Amb a 1-U", "description": "Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 186, "otherNumAffected": 136, "otherNumAtRisk": 186}, {"id": "EG002", "title": "Placebo", "description": "Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks", "seriousNumAffected": 4, "seriousNumAtRisk": 186, "otherNumAffected": 93, "otherNumAtRisk": 186}], "seriousEvents": [{"term": "Pelvic mass", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Soft tissue injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}]}, {"term": "Stab wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}]}, {"term": "Tubulointerstitial nephritis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Pelvic pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Uterine enlargement", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Uterine haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Uterine prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Hypoxia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}, {"term": "Tonsillar hypertrophy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 186}]}], "otherEvents": [{"term": "Ear pruritus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 39, "numAffected": 30, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 33, "numAffected": 30, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 186}]}, {"term": "Lip swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 6, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 16, "numAffected": 14, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 186}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 6, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 16, "numAffected": 13, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 186}]}, {"term": "Oral pruritus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 41, "numAffected": 36, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 44, "numAffected": 36, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 186}]}, {"term": "Paraesthesia oral", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 14, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 28, "numAffected": 20, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 186}]}, {"term": "Swollen tongue", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 22, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 51, "numAffected": 36, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 186}]}, {"term": "Tongue pruritus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 41, "numAffected": 32, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 36, "numAffected": 27, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 186}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 41, "numAffected": 31, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 45, "numAffected": 27, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 42, "numAffected": 33, "numAtRisk": 186}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 9, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 11, "numAffected": 11, "numAtRisk": 186}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 22, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 26, "numAffected": 19, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 38, "numAffected": 28, "numAtRisk": 186}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 14, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 29, "numAffected": 20, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 23, "numAffected": 16, "numAtRisk": 186}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 14, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 16, "numAffected": 15, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 186}]}, {"term": "Dry throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 186}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 15, "numAffected": 13, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 10, "numAffected": 9, "numAtRisk": 186}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 73, "numAffected": 48, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 73, "numAffected": 55, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 13, "numAffected": 10, "numAtRisk": 186}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 13, "numAtRisk": 188}, {"groupId": "EG001", "numEvents": 12, "numAffected": 10, "numAtRisk": 186}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 186}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000001249", "term": "Asthma"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}, {"id": "D000003231", "term": "Conjunctivitis"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}, {"id": "D000003229", "term": "Conjunctival Diseases"}, {"id": "D000005128", "term": "Eye Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M6455", "name": "Conjunctivitis", "asFound": "Conjunctivitis", "relevance": "HIGH"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Rhinitis; Allergic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}, {"id": "M6453", "name": "Conjunctival Diseases", "relevance": "LOW"}, {"id": "M8271", "name": "Eye Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC11", "name": "Eye Diseases"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": true}